Johnson & Johnson is threatening to drop out of its $25.4 billion deal with Guidant. The deal, formally approved yesterday by the FTC, was initially hailed as a windfall for Guidant stockholders and a sound acquisition for J&J. However, J&J is now reconsidering the move since Guidant as issued recalls or warnings for almost 300,000 of its defibrillators and pacemakers and is facing numerous lawsuits as a result. Article [1]
Links:
[1] http://www.iht.com/articles/2005/11/03/business/guidant.php